Clonal spread of fluconazole-resistant C. parapsilosis in patients admitted to a referral hospital located in Burgos, Spain, during the COVID-19 pandemic
© 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd..
BACKGROUND: Fluconazole-resistant Candida parapsilosis (FRCP) is a matter of concern in Spain.
OBJECTIVES: We here report a FRCP spread across a 777-bed referral hospital located in Burgos, Spain, during the COVID-19 pandemic.
PATIENTS/METHODS: In April 2021, an FRCP isolate (MIC = 64 mg/L, E-test®) from a hospitalised patient was detected. Up to June 2022, all C. parapsilosis isolates (n = 35) from hospitalised patients (n = 32) were stored and genotyped using microsatellite markers, and their antifungal susceptibilities were studied (EUCAST); FRCP isolates were molecularly characterised.
RESULTS: We detected 26 FRCP isolates collected between 2021 (n = 8) and 2022 (n = 18); isolates were susceptible to amphotericin B, echinocandins and ibrexafungerp. FRCP isolates were grouped into three genotypes: CP-707 and CP-708 involved isolates harbouring the Y132F + R398I ERG11p substitutions (n = 24) and were clonally related; the remaining CP-675 genotype involved isolates harbouring the G458S ERG11p substitution (n = 2). FRCP genotypes were genetically related to the FRCP genotypes found in Madrid and were unrelated to fluconazole-susceptible ones. Patients harbouring FRCP were mainly (n = 22/23) admitted to intensive care units. Most patients had received broad-spectrum antibiotics (n = 22/23), and/or antifungal therapy with azoles (n = 14/23) within the 30 days prior to FRCP isolation. Thirteen patients were colonised, 10 of whom were infected and presented candidaemia (n = 8/10), endovascular infection (n = 1/10) or complicated urinary infection (n = 1/10). Overall nonattributable 30-day mortality was 17% (n = 4/23).
CONCLUSIONS: We report an outbreak caused by FRCP affecting patients admitted to the ICU of a referral hospital located in Burgos. Patients harbouring FRCP had a higher fluconazole use than those carrying susceptible isolates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Mycoses - 67(2024), 1 vom: 31. Jan., Seite e13685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mantecón-Vallejo, María de Los Ángeles [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8VZV102JFY |
|---|
| Anmerkungen: |
Date Completed 30.01.2024 Date Revised 30.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/myc.13685 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367727714 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367727714 | ||
| 003 | DE-627 | ||
| 005 | 20240130232212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/myc.13685 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM367727714 | ||
| 035 | |a (NLM)38282359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mantecón-Vallejo, María de Los Ángeles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clonal spread of fluconazole-resistant C. parapsilosis in patients admitted to a referral hospital located in Burgos, Spain, during the COVID-19 pandemic |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2024 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Fluconazole-resistant Candida parapsilosis (FRCP) is a matter of concern in Spain | ||
| 520 | |a OBJECTIVES: We here report a FRCP spread across a 777-bed referral hospital located in Burgos, Spain, during the COVID-19 pandemic | ||
| 520 | |a PATIENTS/METHODS: In April 2021, an FRCP isolate (MIC = 64 mg/L, E-test®) from a hospitalised patient was detected. Up to June 2022, all C. parapsilosis isolates (n = 35) from hospitalised patients (n = 32) were stored and genotyped using microsatellite markers, and their antifungal susceptibilities were studied (EUCAST); FRCP isolates were molecularly characterised | ||
| 520 | |a RESULTS: We detected 26 FRCP isolates collected between 2021 (n = 8) and 2022 (n = 18); isolates were susceptible to amphotericin B, echinocandins and ibrexafungerp. FRCP isolates were grouped into three genotypes: CP-707 and CP-708 involved isolates harbouring the Y132F + R398I ERG11p substitutions (n = 24) and were clonally related; the remaining CP-675 genotype involved isolates harbouring the G458S ERG11p substitution (n = 2). FRCP genotypes were genetically related to the FRCP genotypes found in Madrid and were unrelated to fluconazole-susceptible ones. Patients harbouring FRCP were mainly (n = 22/23) admitted to intensive care units. Most patients had received broad-spectrum antibiotics (n = 22/23), and/or antifungal therapy with azoles (n = 14/23) within the 30 days prior to FRCP isolation. Thirteen patients were colonised, 10 of whom were infected and presented candidaemia (n = 8/10), endovascular infection (n = 1/10) or complicated urinary infection (n = 1/10). Overall nonattributable 30-day mortality was 17% (n = 4/23) | ||
| 520 | |a CONCLUSIONS: We report an outbreak caused by FRCP affecting patients admitted to the ICU of a referral hospital located in Burgos. Patients harbouring FRCP had a higher fluconazole use than those carrying susceptible isolates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Candida parapsilosis | |
| 650 | 4 | |a EUCAST | |
| 650 | 4 | |a Y132F | |
| 650 | 4 | |a fluconazole | |
| 650 | 4 | |a resistance | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Mesquida, Aina |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, María de Valle |e verfasserin |4 aut | |
| 700 | 1 | |a Buzón-Martín, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Ossa-Echeverri, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Fisac-Cuadrado, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Megías-Lobón, Gregoria |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega-Lafont, María Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Escribano, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Guinea, Jesús |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycoses |d 1990 |g 67(2024), 1 vom: 31. Jan., Seite e13685 |w (DE-627)NLM01265194X |x 1439-0507 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2024 |g number:1 |g day:31 |g month:01 |g pages:e13685 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/myc.13685 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2024 |e 1 |b 31 |c 01 |h e13685 | ||